News

Live Streaming of Demystifying Pyrazinamide Workshop–September 5 & 6

On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS Research, and the Stop TB Partnership Working Group on New Drugs. There will be live streaming available. The links for each day of the workshop are:

Wednesday, Sept 5: http://webcast.jhu.edu/mediasite/Viewer/?peid=3b4755fe8625440a8ea96b43b353a2551d

Thursday, Sept 6: http://webcast.jhu.edu/mediasite/Viewer/?peid=688e4fd4f60140a4955c208894e334d71d

CLICK HERE FOR FULL AGENDA

Purpose: The workshop aims to highlight ongoing PZA research, provide overview of current knowledge, identify knowledge gaps, identify potential collaborations, establish priorities and strategies to achieve objectives, and perhaps identify more research funding.

The focus of the workshop is intended to improve the use of PZA in any way that makes sense in the context of combo therapy. As a single drug for treatment use, PZA is not relevant. But how it can be improved within combinations is the ultimate aim, including improved and rapid susceptibility testing.

Note: Presentations will be archived and made available to the public on a meeting page that can be accessed from the “Meetings” tab on the main menu at www.newtbdrugs.org shortly after the conclusion of the workshop.

More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...